These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
5. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119 [TBL] [Abstract][Full Text] [Related]
6. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
7. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Rabey JM; Vardi J; Askenazi JJ; Streifler M Gerontology; 1977; 23(6):438-44. PubMed ID: 892450 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies to prevent motor complications in Parkinson's disease. Kieburtz K J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085 [TBL] [Abstract][Full Text] [Related]
9. [L-dopa-induced psychoses and their treatment with L-tryptophan]. Demling J Fortschr Med; 1986 Apr; 104(17):360-2. PubMed ID: 3710403 [No Abstract] [Full Text] [Related]
10. [Motor complications in patients with Parkinson disease treated with levodopa]. Luquin MR; Obeso JA; MartÃnez-Lage JM Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806 [TBL] [Abstract][Full Text] [Related]
11. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Cedarbaum JM; Gandy SE; McDowell FH Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475 [TBL] [Abstract][Full Text] [Related]
12. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Ko WK; Li Q; Bezard E Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591 [TBL] [Abstract][Full Text] [Related]
14. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Sweet RD; McDowell FH; Feigenson JS; Loranger AW; Goodell H Neurology; 1976 Apr; 26(4):305-10. PubMed ID: 944387 [TBL] [Abstract][Full Text] [Related]
15. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647 [TBL] [Abstract][Full Text] [Related]
16. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688 [TBL] [Abstract][Full Text] [Related]
17. L-tryptophan in the treatment of levodopa induced psychiatric disorders. Miller EM; Nieburg HA Dis Nerv Syst; 1974 Jan; 35(1):20-3. PubMed ID: 17894051 [TBL] [Abstract][Full Text] [Related]
18. Serotonin and Parkinson's disease. Hesselink JM Am J Psychiatry; 1993 May; 150(5):843-4. PubMed ID: 8480847 [No Abstract] [Full Text] [Related]
19. [Treatment of Parkinson's disease with multiple drugs]. Kuno S Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424 [TBL] [Abstract][Full Text] [Related]